Patents by Inventor Toshiyoshi Fujiwara
Toshiyoshi Fujiwara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041960Abstract: In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell agent comprising an oncolytic virus comprising a p53 gene. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell preparation comprising a recombinant virus comprising: a first gene cassette containing a telomerase reverse transcriptase promoter, an E1A gene, an IRES sequence and an E1B gene; and a second gene cassette containing a promoter and a p53 gene.Type: ApplicationFiled: August 14, 2023Publication date: February 8, 2024Applicants: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, Oncolys BioPharma Inc.Inventors: Toshiyoshi FUJIWARA, Toshihiro OGAWA, Takeyoshi NISHIYAMA, Satoru KIKUCHI, Hiroshi TAZAWA
-
Publication number: 20210393715Abstract: In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell agent comprising an oncolytic virus comprising a p53 gene. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell preparation comprising a recombinant virus comprising: a first gene cassette containing a telomerase reverse transcriptase promoter, an E1A gene, an IRES sequence and an E1B gene; and a second gene cassette containing a promoter and a p53 gene.Type: ApplicationFiled: June 21, 2021Publication date: December 23, 2021Applicants: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, Oncolys BioPharma Inc.Inventors: Toshiyoshi FUJIWARA, Toshihiro OGAWA, Takeyoshi NISHIYAMA, Satoru KIKUCHI, Hiroshi TAZAWA
-
Patent number: 8163892Abstract: By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect.Type: GrantFiled: July 19, 2010Date of Patent: April 24, 2012Assignee: Oncolys Biopharma, Inc.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo, Yoshiko Shirakiya, Takeshi Kawashima
-
Patent number: 7943373Abstract: The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.Type: GrantFiled: June 21, 2005Date of Patent: May 17, 2011Assignee: Oncolys Biopharma, Inc.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo, Hiroyuki Mizuguchi, Takao Hayakawa
-
Publication number: 20110111480Abstract: The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.Type: ApplicationFiled: September 30, 2010Publication date: May 12, 2011Applicant: ONCOLYS BIOPHARMA INC.Inventors: TOSHIYOSHI FUJIWARA, NORIAKI TANAKA, SATORU KYO, HIROYUKI MIZUGUCHI, TAKAO HAYAKAWA
-
Publication number: 20110044949Abstract: By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect.Type: ApplicationFiled: July 19, 2010Publication date: February 24, 2011Applicants: KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD., ONCOLYS BIOPHARMA, INC.Inventors: Toshiyoshi FUJIWARA, Noriaki TANAKA, Satoru KYO, Yoshiko SHIRAKIYA, Takeshi KAWASHIMA
-
Publication number: 20100150884Abstract: The present invention relates to providing a pharmaceutical composition with a still more enhanced anticancer activity. Specifically, the present invention relates to a pharmaceutical composition for combination therapy for tumors, comprising a recombinant virus comprising a polynucleotide containing a promoter for human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order, and a substance having an antitumor effect.Type: ApplicationFiled: February 10, 2006Publication date: June 17, 2010Applicant: Oncolys BioPharma Inc.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo
-
Publication number: 20090181931Abstract: The present invention relates to pyrimidine compounds and their use as pharmacologically active agents capable of suppressing and inhibiting viruses (e.g., oncolytic viruses). The subject compounds and compositions are particularly useful in treating and suppressing human oncolytic adenovirus infection.Type: ApplicationFiled: January 16, 2008Publication date: July 16, 2009Applicant: ONCOLYS BIOPHARMA, INC.Inventors: Yasuo Urata, Masaaki Ouchi, Toshiyoshi Fujiwara
-
Patent number: 7521234Abstract: The present invention provides a mammalian immortalized liver cell obtained by transferring a cell proliferation factor gene located between a pair of site-specific recombination sequences into a mammalian liver cell.Type: GrantFiled: March 15, 2002Date of Patent: April 21, 2009Inventors: Naoya Kobayashi, Philippe Leboulch, Noriaki Tanaka, Toshiyoshi Fujiwara, Toshinori Totsugawa
-
Publication number: 20080233642Abstract: The present invention provides a mammalian immortalized liver cell obtained by transferring a cell proliferation factor gene located between a pair of site-specific recombination sequences into a mammalian liver cell.Type: ApplicationFiled: March 15, 2002Publication date: September 25, 2008Inventors: Naoya Kobayashi, Philippe Leboulch, Noriaki Tanaka, Toshiyoshi Fujiwara, Toshinori Totsugawa
-
Publication number: 20080032283Abstract: The present invention relates to providing a reagent for cancer cell detection or cancer diagnosis, a pharmaceutical composition for the treatment of cancer, and a method of treating or preventing cancer in a subject. Specifically, the present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.Type: ApplicationFiled: April 5, 2007Publication date: February 7, 2008Applicant: ONCOLYS BIOPHARMA INC.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo, Hiroyuki Mizuguchi, Takao Hayakawa
-
Publication number: 20060239967Abstract: By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect.Type: ApplicationFiled: July 7, 2003Publication date: October 26, 2006Applicant: Kansai Technology Licensing Organization Co., Ltd.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo, Yoshiko Shirakiya, Takeshi Kawashima
-
Patent number: 7109179Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: February 23, 2004Date of Patent: September 19, 2006Assignee: Board of Regents, the University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Publication number: 20060182718Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: ApplicationFiled: February 6, 2006Publication date: August 17, 2006Inventors: Jack Roth, Toshiyoshi Fujiwara, Elizabeth Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie Owen-Schaub
-
Patent number: 7033744Abstract: The present invention provides a method comprising a step of transferring a cell proliferation factor gene into a mammalian liver cell to obtain an immortalized liver cell, a step of proliferating the immortalized liver cell, and a step of removing the cell proliferation factor gene from the immortalized liver cell; a large number of liver cells obtained thereby; and a treating agent and a artificial liver comprising obtained liver cell.Type: GrantFiled: March 15, 2002Date of Patent: April 25, 2006Inventors: Naoya Kobayashi, Philippe Leboulch, Noriaki Tanaka, Toshiyoshi Fujiwara, Toshinori Totsugawa
-
Publication number: 20060067890Abstract: The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.Type: ApplicationFiled: June 21, 2005Publication date: March 30, 2006Applicant: Oncolys BioPharma Inc.Inventors: Toshiyoshi Fujiwara, Noriaki Tanaka, Satoru Kyo, Hiroyuki Mizuguchi, Takao Hayakawa
-
Publication number: 20050089511Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: ApplicationFiled: February 23, 2004Publication date: April 28, 2005Inventors: Jack Roth, Toshiyoshi Fujiwara, Elizabeth Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie Owen-Schaub
-
Patent number: 6797702Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: August 26, 1997Date of Patent: September 28, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Publication number: 20040048374Abstract: The present invention provides a mammalian immortalized liver cell obtained by transferring a cell proliferation factor gene located between a pair of site-specific recombination sequences into a mammalian liver cell.Type: ApplicationFiled: January 6, 2003Publication date: March 11, 2004Inventors: Naoya Kobayashi, Philippe Leboulch, Noriaki Tanaka, Toshiyoshi Fujiwara, Toshinori Totsugawa
-
Publication number: 20040033215Abstract: The present invention provides a method comprising a step of transferring a cell proliferation factor gene into a mammalian liver cell to obtain an immortalized liver cell, a step of proliferating the immortalized liver cell, and a step of removing the cell proliferation factor gene from the immortalized liver cell; a large number of liver cells obtained thereby; and a treating agent and a artificial liver comprising obtained liver cell.Type: ApplicationFiled: January 6, 2003Publication date: February 19, 2004Inventors: Naoya Kobayashi, Philippe Leboulch, Noriaki Tanaka, Toshiyoshi Fujiwara, Toshinori Totsugawa